米托蒽醌为主的联合化疗方案治疗复发和难治性血液系统恶性肿瘤患者

Mitoxantrone combined chemotherapy in patients with refractory and relapsed hematopoietic malignancies

目的:观察米托蒽醌联合阿糖胞苷或替尼泊苷（VM26）等其他药物治疗复发和难治性血液恶性肿瘤的疗效及不良反应。方法:急性髓性白血病和慢粒急变采用MA方案,急淋采用VMCP方案,非霍奇金淋巴瘤采用CMOP+VM26方案。定期观察骨髓及血象,并作跟踪随访。结果:18例患者中,一个疗程完全缓解10例（55.6％）,部分缓解3例（16.7％）,未缓解和死亡4例（22.2％）,慢粒急变转入稳定期1例。最常见的不良反应是长时间的骨髓抑制,而其他不良反应均较少。结论:米托蒽醌联合阿糖胞苷等药物化疗,在治疗复发、难治性血液系统恶性肿瘤中具有良好的疗效,且不良反应较少,缓解时间长。

Aim: To investigate the therapeutic and side effect of mitoxantrone combined with cytarabine or teniposide (VM26) in patients with refractory and relapsed hematopoietic malignancies. Methods: Patients with acute myeloid leukemia and blastic phase CML were treated with regimen of MA. VMCP and CMOP plus VM26 were used in the patients with acute lymphoblastic leukemia and non-Hodgkin's lymphoma, respectively. All patients' bone marrow and peripheral blood sample were monitored regularly and most of the patients were followed up closely. Results: In total of the 18 patients, 10 cases (55. 6%) achieved complete remission (CR), 3 cases (16. 7%) had partial remission, 4 cases had no response and death (22.2%), 1 case converted stationary phase from blastic phase CML. The most frequent side effect was long-lasting myelosuppression, but others were rare. Conclusion: Combination treatment containing mitoxantrone in patients with refractory and relapsed hematopoietic malignancies demonstrats a higher therapeutic effect, lower side effect and longer remission.